Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice
Highlights • The small molecule inhibitor of the inflammasome, MC950, attenuates Aβ+LPS-induced inflammasome activation in microglia. • It increases phagocytosis of Aβ by microglia in vitro. • Oral administration of MC950, reduces Aβ accumulation in APP/PS1 mice. • This is accompanied by improved co...
Saved in:
| Published in | Brain, behavior, and immunity Vol. 61; pp. 306 - 316 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Inc
01.03.2017
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Highlights • The small molecule inhibitor of the inflammasome, MC950, attenuates Aβ+LPS-induced inflammasome activation in microglia. • It increases phagocytosis of Aβ by microglia in vitro. • Oral administration of MC950, reduces Aβ accumulation in APP/PS1 mice. • This is accompanied by improved cognitive function and decreased neuroinflammation. |
|---|---|
| AbstractList | Highlights • The small molecule inhibitor of the inflammasome, MC950, attenuates Aβ+LPS-induced inflammasome activation in microglia. • It increases phagocytosis of Aβ by microglia in vitro. • Oral administration of MC950, reduces Aβ accumulation in APP/PS1 mice. • This is accompanied by improved cognitive function and decreased neuroinflammation. Activation of the inflammasome is implicated in the pathogenesis of an increasing number of inflammatory diseases, including Alzheimer's disease (AD). Research reporting inflammatory changes in post mortem brain tissue of individuals with AD and GWAS data have convincingly demonstrated that neuroinflammation is likely to be a key driver of the disease. This, together with the evidence that genetic variants in the NLRP3 gene impact on the risk of developing late-onset AD, indicates that targetting inflammation offers a therapeutic opportunity. Here, we examined the effect of the small molecule inhibitor of the NLRP3 inflammasome, MCC950, on microglia in vitro and in vivo. The findings indicate that MCC950 inhibited LPS+Aβ-induced caspase 1 activation in microglia and this was accompanied by IL-1β release, without inducing pyroptosis. We demonstrate that MCC950 also inhibited inflammasome activation and microglial activation in the APP/PS1 mouse model of AD. Furthermore, MCC950 stimulated Aβ phagocytosis in vitro, and it reduced Aβ accumulation in APP/PS1 mice, which was associated with improved cognitive function. These data suggest that activation of the inflammasome contributes to amyloid accumulation and to the deterioration of neuronal function in APP/PS1 mice and demonstrate that blocking assembly of the inflammasome may prove to be a valuable strategy for attenuating changes that negatively impact on neuronal function. •The small molecule inhibitor of the inflammasome, MC950, attenuates Aβ+LPS-induced inflammasome activation in microglia.•It increases phagocytosis of Aβ by microglia in vitro.•Oral administration of MC950, reduces Aβ accumulation in APP/PS1 mice.•This is accompanied by improved cognitive function and decreased neuroinflammation. Activation of the inflammasome is implicated in the pathogenesis of an increasing number of inflammatory diseases, including Alzheimer’s disease (AD). Research reporting inflammatory changes in post mortem brain tissue of individuals with AD and GWAS data have convincingly demonstrated that neuroinflammation is likely to be a key driver of the disease. This, together with the evidence that genetic variants in the NLRP3 gene impact on the risk of developing late-onset AD, indicates that targetting inflammation offers a therapeutic opportunity. Here, we examined the effect of the small molecule inhibitor of the NLRP3 inflammasome, MCC950, on microglia in vitro and in vivo. The findings indicate that MCC950 inhibited LPS+Aβ-induced caspase 1 activation in microglia and this was accompanied by IL-1β release, without inducing pyroptosis. We demonstrate that MCC950 also inhibited inflammasome activation and microglial activation in the APP/PS1 mouse model of AD. Furthermore, MCC950 stimulated Aβ phagocytosis in vitro, and it reduced Aβ accumulation in APP/PS1 mice, which was associated with improved cognitive function. These data suggest that activation of the inflammasome contributes to amyloid accumulation and to the deterioration of neuronal function in APP/PS1 mice and demonstrate that blocking assembly of the inflammasome may prove to be a valuable strategy for attenuating changes that negatively impact on neuronal function. |
| Author | Bryson, K.J Lynch, M.A Larkin, C Robertson, A.A.B Finucane, O Mills, E.L Dempsey, C O'Neill, L.A.J Rubio Araiz, A Cooper, M.A |
| Author_xml | – sequence: 1 fullname: Dempsey, C – sequence: 2 fullname: Rubio Araiz, A – sequence: 3 fullname: Bryson, K.J – sequence: 4 fullname: Finucane, O – sequence: 5 fullname: Larkin, C – sequence: 6 fullname: Mills, E.L – sequence: 7 fullname: Robertson, A.A.B – sequence: 8 fullname: Cooper, M.A – sequence: 9 fullname: O'Neill, L.A.J – sequence: 10 fullname: Lynch, M.A |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28003153$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc9u1DAQxi1URLeFB-CCfOSS1BPnjy0kpGrFn0oLrCicLccZ73pJ7G2cFO2dJ-JBeCa82sKBA6eZw_d9M_ObC3Lmg0dCngPLgUF9tcvb1uVFanMocgblI7IAJllWAJdnZMGEkBlUEs7JRYw7xljFQTwh54VgjEPFF-THjd-61k3Ob-i0Rfpx9XnNqfO218OgYxiQfnfTln5YLmXF6H4MQ5gw0rRJtt_2YePi5Aw1PepRe4M0WKqHQx9cl_36SbXvqAkbnwbcI7WzN5MLPuXT6_X6an0LdHAGn5LHVvcRnz3US_L17Zsvy_fZ6tO7m-X1KjMlE1PW1GUHAFLoppElw64ThW6YKGWX2qaVnFfcmoaD1rqxEoxE0dhKFsZCZZFfkpen3HTG3YxxUoOLBvteewxzVCAqqKXgvElSOEnNGGIc0ar96AY9HhQwdYSvdirBV0f4CgqV4CfPi4f4uR2w--v4QzsJXp0EmI68dziqaBwmap0b0UyqC-6_8a__cZveeWd0_w0PGHdhHn2ip0DFZFC3x-8fnw81Z1XNBP8NTuarkQ |
| CitedBy_id | crossref_primary_10_1016_j_molmet_2018_02_001 crossref_primary_10_3233_JAD_230567 crossref_primary_10_1007_s10753_018_0894_4 crossref_primary_10_1016_j_physbeh_2023_114348 crossref_primary_10_1126_sciadv_abb9036 crossref_primary_10_1016_j_pharmthera_2021_108053 crossref_primary_10_1016_j_biopha_2021_111428 crossref_primary_10_1016_j_intimp_2023_111030 crossref_primary_10_1177_20587392211058615 crossref_primary_10_3390_ijms19123977 crossref_primary_10_1002_cti2_1247 crossref_primary_10_1016_j_bmcl_2017_12_054 crossref_primary_10_3389_fncel_2021_749587 crossref_primary_10_3390_ijms22031271 crossref_primary_10_1021_acs_jmedchem_0c01924 crossref_primary_10_3164_jcbn_22_105 crossref_primary_10_3390_ijms20030558 crossref_primary_10_1124_pharmrev_120_000171 crossref_primary_10_3390_ijms24087258 crossref_primary_10_1016_j_molmed_2023_10_001 crossref_primary_10_1016_j_neubiorev_2022_104969 crossref_primary_10_1016_j_arr_2023_102098 crossref_primary_10_3390_ijms22052523 crossref_primary_10_4103_1673_5374_391311 crossref_primary_10_1186_s12974_019_1459_7 crossref_primary_10_1016_j_biopha_2019_109618 crossref_primary_10_1124_pharmrev_122_000629 crossref_primary_10_1007_s12640_021_00459_2 crossref_primary_10_1016_j_pharmthera_2018_02_011 crossref_primary_10_1021_acschemneuro_3c00343 crossref_primary_10_3390_biom10040562 crossref_primary_10_1007_s12640_022_00554_y crossref_primary_10_1016_j_phymed_2023_154695 crossref_primary_10_3389_fimmu_2020_00754 crossref_primary_10_3390_biom13111568 crossref_primary_10_1186_s12974_018_1299_x crossref_primary_10_3390_ijms231810235 crossref_primary_10_1016_j_neulet_2021_136290 crossref_primary_10_1007_s12035_020_02082_2 crossref_primary_10_3389_fphys_2022_965366 crossref_primary_10_1016_j_neuroscience_2023_11_004 crossref_primary_10_1038_s41420_021_00434_y crossref_primary_10_1111_bph_14569 crossref_primary_10_1016_j_bbrc_2020_03_161 crossref_primary_10_1016_j_redox_2024_103123 crossref_primary_10_1111_jnc_15788 crossref_primary_10_2337_dbi21_0013 crossref_primary_10_1038_s41577_019_0165_0 crossref_primary_10_1016_j_coph_2021_01_003 crossref_primary_10_3389_fnagi_2020_00119 crossref_primary_10_1186_s12886_020_01565_z crossref_primary_10_3389_fimmu_2022_859703 crossref_primary_10_1016_j_nbd_2023_106142 crossref_primary_10_1073_pnas_1916318116 crossref_primary_10_1186_s12974_019_1498_0 crossref_primary_10_3892_ijmm_2023_5238 crossref_primary_10_1186_s12964_023_01038_y crossref_primary_10_2174_1567205020666230203112351 crossref_primary_10_2174_1570159X20666220327215245 crossref_primary_10_1016_j_biopha_2022_113229 crossref_primary_10_1002_mnfr_201801230 crossref_primary_10_15252_emmm_201708259 crossref_primary_10_1186_s12974_021_02322_9 crossref_primary_10_3390_toxins13120880 crossref_primary_10_1038_s41419_020_03072_x crossref_primary_10_1038_s41380_020_00971_5 crossref_primary_10_1186_s12882_021_02391_1 crossref_primary_10_1007_s00401_018_01957_y crossref_primary_10_1007_s12035_023_03618_y crossref_primary_10_1016_j_bbi_2023_11_031 crossref_primary_10_3390_ijms231710168 crossref_primary_10_3390_metabo12111099 crossref_primary_10_1016_j_exger_2023_112307 crossref_primary_10_1007_s11481_024_10101_5 crossref_primary_10_1038_s41419_019_1413_8 crossref_primary_10_1155_2021_5551578 crossref_primary_10_1002_rcm_8694 crossref_primary_10_1016_j_arr_2019_100966 crossref_primary_10_1038_s41573_023_00822_2 crossref_primary_10_1016_j_ejmcr_2022_100100 crossref_primary_10_1002_mds_27874 crossref_primary_10_1111_bpa_13142 crossref_primary_10_1186_s12974_020_01933_y crossref_primary_10_1186_s13024_023_00674_9 crossref_primary_10_1016_j_intimp_2023_111236 crossref_primary_10_1186_s12974_020_01842_0 crossref_primary_10_1097_WNR_0000000000001429 crossref_primary_10_3389_fnmol_2022_910298 crossref_primary_10_1186_s12974_020_01902_5 crossref_primary_10_1523_JNEUROSCI_1980_20_2020 crossref_primary_10_3390_ijms23168979 crossref_primary_10_3389_fnagi_2022_825086 crossref_primary_10_1002_adbi_202101166 crossref_primary_10_1038_s41419_021_03397_1 crossref_primary_10_1016_j_bbi_2020_01_012 crossref_primary_10_1186_s12974_019_1453_0 crossref_primary_10_1007_s12035_023_03235_9 crossref_primary_10_1186_s12950_021_00268_6 crossref_primary_10_1007_s00394_019_02128_9 crossref_primary_10_1007_s10571_020_00957_5 crossref_primary_10_1038_s41598_019_40619_1 crossref_primary_10_1084_jem_20171419 crossref_primary_10_3389_fnagi_2021_809433 crossref_primary_10_1016_j_imlet_2020_10_004 crossref_primary_10_3389_fnagi_2022_879021 crossref_primary_10_1016_j_jbc_2024_107306 crossref_primary_10_3389_fmed_2021_798334 crossref_primary_10_1111_bpa_12704 crossref_primary_10_3389_fcvm_2024_1420067 crossref_primary_10_1038_s41598_023_35945_4 crossref_primary_10_3390_cells11121925 crossref_primary_10_3390_molecules23030522 crossref_primary_10_1016_j_brainresbull_2020_09_017 crossref_primary_10_1111_cpr_13137 crossref_primary_10_1007_s11481_021_10037_0 crossref_primary_10_3389_fphar_2020_584184 crossref_primary_10_1038_s41467_018_04947_6 crossref_primary_10_2174_1871530322666220407090916 crossref_primary_10_1186_s12974_021_02295_9 crossref_primary_10_3389_fncel_2017_00063 crossref_primary_10_3390_ijms22115603 crossref_primary_10_1016_j_jmb_2021_167379 crossref_primary_10_1248_bpb_b20_00112 crossref_primary_10_1016_j_neuroscience_2023_12_006 crossref_primary_10_1371_journal_pone_0257211 crossref_primary_10_1155_2023_5149306 crossref_primary_10_1016_j_bbi_2020_11_004 crossref_primary_10_1016_j_foodres_2023_112567 crossref_primary_10_1016_j_brainresbull_2022_09_007 crossref_primary_10_14336_AD_2023_0926_1 crossref_primary_10_1021_acschembio_1c00218 crossref_primary_10_3389_fnint_2020_00037 crossref_primary_10_1016_j_phrs_2022_106404 crossref_primary_10_3389_fnmol_2022_847440 crossref_primary_10_3389_fncel_2019_00073 crossref_primary_10_1186_s12974_023_02709_w crossref_primary_10_3233_JAD_231159 crossref_primary_10_3389_fphar_2019_00840 crossref_primary_10_1007_s11064_020_03121_z crossref_primary_10_1016_j_intimp_2023_110287 crossref_primary_10_1097_SHK_0000000000001832 crossref_primary_10_3389_fimmu_2023_1117172 crossref_primary_10_3389_fimmu_2023_1128700 crossref_primary_10_1186_s43556_024_00179_x crossref_primary_10_3389_fneur_2018_01062 crossref_primary_10_1186_s12974_018_1281_7 crossref_primary_10_1016_j_bmcl_2022_128601 crossref_primary_10_3390_ijms22031093 crossref_primary_10_1177_2472555218786210 crossref_primary_10_3389_fcell_2021_630479 crossref_primary_10_1016_j_jstrokecerebrovasdis_2019_104468 crossref_primary_10_1016_j_redox_2020_101538 crossref_primary_10_1007_s12035_021_02661_x crossref_primary_10_1016_j_intimp_2020_107358 crossref_primary_10_1080_00207454_2021_1922402 crossref_primary_10_1016_j_clim_2019_04_004 crossref_primary_10_1186_s12974_022_02419_9 crossref_primary_10_3389_fimmu_2019_01827 crossref_primary_10_1016_j_intimp_2020_106263 crossref_primary_10_1111_nan_12483 crossref_primary_10_1007_s12035_021_02683_5 crossref_primary_10_3233_JAD_210268 crossref_primary_10_1186_s12882_023_03427_4 crossref_primary_10_1007_s00044_021_02740_7 crossref_primary_10_3389_fnmol_2022_774014 crossref_primary_10_1002_ana_26158 crossref_primary_10_1111_cea_13190 crossref_primary_10_1186_s12974_023_02698_w crossref_primary_10_3390_molecules29030712 crossref_primary_10_1111_jphp_13332 crossref_primary_10_3390_biom9120850 crossref_primary_10_3389_fnmol_2020_609073 crossref_primary_10_1016_j_lfs_2019_117043 crossref_primary_10_1097_WNR_0000000000001752 crossref_primary_10_1007_s12035_020_02089_9 crossref_primary_10_1007_s12035_024_03914_1 crossref_primary_10_3389_fnmol_2022_894298 crossref_primary_10_1089_neu_2017_5344 crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107670 crossref_primary_10_3389_fimmu_2022_766919 crossref_primary_10_3390_futurepharmacol3040048 crossref_primary_10_12677_ACM_2021_1112905 crossref_primary_10_1016_j_celrep_2024_114070 crossref_primary_10_3389_fcell_2022_821225 crossref_primary_10_1016_j_neuron_2020_09_029 crossref_primary_10_1016_j_neuroscience_2024_03_029 crossref_primary_10_15252_emmm_201708689 crossref_primary_10_1016_j_bbi_2024_02_001 crossref_primary_10_1038_s41598_020_61630_x crossref_primary_10_1016_j_intimp_2022_108595 crossref_primary_10_1016_j_jmb_2021_167183 crossref_primary_10_1016_j_ejphar_2024_176370 crossref_primary_10_2174_1381612826666200113162641 crossref_primary_10_1016_j_phrs_2021_106033 crossref_primary_10_1038_s41386_021_01056_9 crossref_primary_10_1007_s11064_020_03063_6 crossref_primary_10_3389_fphar_2023_1125982 crossref_primary_10_3390_cells12232709 crossref_primary_10_1038_s41419_021_04349_5 crossref_primary_10_1111_bph_16243 crossref_primary_10_1016_j_biopha_2022_113851 crossref_primary_10_2139_ssrn_4189328 crossref_primary_10_3389_fimmu_2019_02538 crossref_primary_10_1007_s00109_019_01753_5 crossref_primary_10_3389_fnmol_2020_00094 crossref_primary_10_1016_j_arr_2020_101202 crossref_primary_10_1080_1028415X_2021_1913952 crossref_primary_10_1016_j_jneuroim_2021_577543 crossref_primary_10_1038_s41419_020_03076_7 crossref_primary_10_3389_fnagi_2023_1284214 crossref_primary_10_1016_j_nbd_2018_02_016 crossref_primary_10_1111_bph_14618 crossref_primary_10_15252_emmm_201911185 crossref_primary_10_1002_ctm2_1449 crossref_primary_10_3390_cells9102183 crossref_primary_10_1177_1747493019841242 crossref_primary_10_2139_ssrn_4178538 crossref_primary_10_3389_fnmol_2022_805169 crossref_primary_10_3389_fphar_2022_845185 crossref_primary_10_3389_fphar_2021_707696 crossref_primary_10_3389_fnagi_2022_1065183 crossref_primary_10_3389_fimmu_2022_1021351 crossref_primary_10_3390_ijms24031869 crossref_primary_10_1089_neu_2023_0444 crossref_primary_10_1007_s12035_021_02650_0 crossref_primary_10_1111_imm_13402 crossref_primary_10_1096_fj_202301922RR crossref_primary_10_1016_j_molmed_2020_06_005 crossref_primary_10_1016_j_neuroscience_2023_02_005 crossref_primary_10_1038_s41583_018_0055_7 crossref_primary_10_3389_fcell_2020_00588 crossref_primary_10_3390_brainsci14010096 crossref_primary_10_3390_ijms23095056 crossref_primary_10_1038_s41598_021_94850_w crossref_primary_10_3389_fphar_2021_643254 crossref_primary_10_1186_s12974_020_02018_6 crossref_primary_10_4103_1673_5374_224362 crossref_primary_10_3389_fnagi_2023_1201982 crossref_primary_10_1038_s41380_023_02239_0 crossref_primary_10_3233_JAD_230273 crossref_primary_10_3389_fimmu_2024_1323409 crossref_primary_10_1186_s12974_020_01778_5 crossref_primary_10_15252_emmm_201810248 crossref_primary_10_3390_cimb45110540 crossref_primary_10_1161_JAHA_119_014044 crossref_primary_10_1038_s41392_023_01486_5 crossref_primary_10_3390_ijms22031324 crossref_primary_10_3389_fphar_2020_626502 crossref_primary_10_1016_j_neuropharm_2024_109941 crossref_primary_10_1016_j_neuint_2021_105220 crossref_primary_10_3233_ADR_200170 crossref_primary_10_3389_fnagi_2022_1018848 crossref_primary_10_1038_s41380_019_0542_x crossref_primary_10_1016_j_mam_2020_100889 crossref_primary_10_1016_j_arr_2022_101654 crossref_primary_10_3390_ijms222111338 crossref_primary_10_3390_molecules26164996 crossref_primary_10_37349_ei_2022_00048 crossref_primary_10_1093_brain_awad375 crossref_primary_10_1016_j_tins_2019_11_005 crossref_primary_10_3390_ijms25116078 crossref_primary_10_1016_j_lfs_2022_121352 crossref_primary_10_3389_fncel_2018_00426 crossref_primary_10_1021_acsmedchemlett_2c00242 crossref_primary_10_1111_imm_13291 crossref_primary_10_3390_biomedicines9050524 crossref_primary_10_3390_cells9030577 crossref_primary_10_1016_j_intimp_2024_112168 crossref_primary_10_3390_molecules26040953 crossref_primary_10_1016_j_trsl_2022_08_006 crossref_primary_10_1177_10738584211070273 crossref_primary_10_1016_j_jneuroim_2018_11_010 crossref_primary_10_1016_j_nbd_2023_106001 crossref_primary_10_1016_j_mce_2021_111529 crossref_primary_10_1016_j_trsl_2022_08_004 crossref_primary_10_1093_braincomms_fcaa109 crossref_primary_10_3390_molecules27134124 crossref_primary_10_1002_ptr_7014 crossref_primary_10_1038_s42003_021_02259_y crossref_primary_10_1039_D1SC06071F crossref_primary_10_1016_j_drudis_2022_01_004 crossref_primary_10_1146_annurev_med_050715_104343 crossref_primary_10_3233_JAD_210400 crossref_primary_10_1016_j_intimp_2024_111869 crossref_primary_10_1029_2023GH000888 crossref_primary_10_4103_1673_5374_286951 crossref_primary_10_1002_ptr_6849 crossref_primary_10_1007_s00044_020_02687_1 crossref_primary_10_1038_nrd_2018_97 crossref_primary_10_1155_2022_6091671 crossref_primary_10_3389_fimmu_2021_701282 crossref_primary_10_1038_s41598_023_39805_z crossref_primary_10_1523_JNEUROSCI_0682_21_2021 crossref_primary_10_1186_s40035_023_00381_x crossref_primary_10_1007_s13311_019_00792_7 crossref_primary_10_5483_BMBRep_2020_53_1_274 crossref_primary_10_1038_s41419_020_2565_2 crossref_primary_10_1016_j_tins_2023_07_009 crossref_primary_10_3389_fnins_2020_549772 crossref_primary_10_1016_j_bbi_2020_03_011 crossref_primary_10_1016_j_neuropharm_2020_108305 crossref_primary_10_1186_s12974_018_1319_x crossref_primary_10_1038_s41598_018_24350_x crossref_primary_10_1016_j_intimp_2019_05_054 crossref_primary_10_1021_acsbiomedchemau_3c00063 crossref_primary_10_1186_s12974_022_02547_2 crossref_primary_10_1186_s12964_024_01591_0 crossref_primary_10_1016_j_intimp_2020_106317 crossref_primary_10_1016_j_bbi_2020_04_058 crossref_primary_10_1038_s41419_020_2460_x crossref_primary_10_3389_fnagi_2018_00332 crossref_primary_10_1007_s12035_020_01909_2 crossref_primary_10_1016_j_arr_2020_101192 crossref_primary_10_4103_1673_5374_303007 crossref_primary_10_1007_s12035_017_0467_9 crossref_primary_10_1016_j_jnrt_2024_100106 crossref_primary_10_1016_j_tips_2022_04_003 crossref_primary_10_3389_fncel_2020_00276 crossref_primary_10_3390_cells11040729 crossref_primary_10_3389_fimmu_2020_604179 crossref_primary_10_1080_13813455_2022_2093377 crossref_primary_10_3892_ijmm_2023_5314 crossref_primary_10_1007_s12035_023_03229_7 crossref_primary_10_1080_08923973_2021_1925293 crossref_primary_10_30629_2658_7947_2021_26_5_4_15 crossref_primary_10_3389_fimmu_2023_1190219 crossref_primary_10_1186_s13062_023_00387_5 crossref_primary_10_2174_1570159X18666200621204546 crossref_primary_10_1007_s12035_022_03067_z crossref_primary_10_1007_s12035_020_02184_x crossref_primary_10_3389_fnins_2022_922331 crossref_primary_10_3390_jpm11100963 crossref_primary_10_1155_2021_1020614 crossref_primary_10_3233_JAD_210660 crossref_primary_10_3390_biomedicines11071800 crossref_primary_10_1155_2022_4759963 crossref_primary_10_1016_j_bbi_2021_08_230 crossref_primary_10_4103_1673_5374_272576 crossref_primary_10_1007_s13311_022_01201_2 crossref_primary_10_1016_j_bbr_2022_113879 crossref_primary_10_1111_imr_12908 crossref_primary_10_3390_biomedicines11040999 crossref_primary_10_2174_1574885518666230427100702 crossref_primary_10_1016_j_bioorg_2021_104681 crossref_primary_10_1038_cddis_2017_308 crossref_primary_10_3390_ijms21239036 crossref_primary_10_1016_j_bbrc_2020_11_009 crossref_primary_10_3233_JAD_181259 crossref_primary_10_1002_adbi_202000037 |
| Cites_doi | 10.1007/s12017-013-8274-6 10.1172/JCI31450 10.1016/j.jneuroim.2013.10.002 10.1038/nm.3806 10.1111/imr.12285 10.1016/j.neurobiolaging.2013.12.026 10.1016/j.immuni.2009.08.001 10.1038/ni.1636 10.1016/j.neurobiolaging.2016.04.001 10.1038/ni.3538 10.4049/jimmunol.1100620 10.4049/jimmunol.1200947 10.1186/1742-2094-9-126 10.1016/S1389-0344(01)00067-3 10.1186/s12974-015-0411-8 10.1186/s13024-016-0088-1 10.1038/nature11729 10.1016/j.bbi.2015.01.005 10.1523/JNEUROSCI.4361-12.2013 10.1073/pnas.86.19.7611 10.1111/imr.12296 10.1016/j.neurobiolaging.2015.04.018 10.1016/j.biopsych.2014.05.006 |
| ContentType | Journal Article |
| Copyright | 2016 Elsevier Inc. Copyright © 2016 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2016 Elsevier Inc. – notice: Copyright © 2016 Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1016/j.bbi.2016.12.014 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1090-2139 |
| EndPage | 316 |
| ExternalDocumentID | 10_1016_j_bbi_2016_12_014 28003153 S0889159116305608 1_s2_0_S0889159116305608 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 23N 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ 9JM 9JO AAAJQ AACTN AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXKI AAXLA AAXUO ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABOYX ABXDB ACDAQ ACGFO ACGFS ACRLP ACXNI ADBBV ADEZE ADFGL ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFJKZ AFKWA AFRHN AFTJW AFXIZ AGEKW AGHFR AGUBO AGWIK AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CAG CJTIS COF CS3 DM4 DU5 EBS EFBJH EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMG HMQ HVGLF HZ~ IHE J1W KOM L7B LG5 LUGTX LZ5 M2U M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SIN SNS SPCBC SSB SSI SSN SSY SSZ T5K TN5 UAP UNMZH UPT WUQ XPP XSW Z5R ZGI ZMT ~G- ~S- AADPK AAIAV ABYKQ AFYLN AJBFU EFLBG CGR CUY CVF ECM EIF NPM AAYXX ACRPL ADNMO CITATION 7X8 |
| ID | FETCH-LOGICAL-c408t-764d11198a77940edd82a70849ddd87b93353fc731aaa7f91c9e87f592cf15fe3 |
| IEDL.DBID | AIKHN |
| ISSN | 0889-1591 |
| IngestDate | Fri Oct 25 23:03:27 EDT 2024 Fri Dec 06 02:49:37 EST 2024 Sat Sep 28 08:48:23 EDT 2024 Fri Feb 23 02:27:20 EST 2024 Tue Oct 15 22:55:20 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | APP/PS1 mice Interleukin-1β Neuroinflammation Caspase 1 Inflammasome Alzheimer's disease Microglia Alzheimer’s disease |
| Language | English |
| License | Copyright © 2016 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c408t-764d11198a77940edd82a70849ddd87b93353fc731aaa7f91c9e87f592cf15fe3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 28003153 |
| PQID | 1851698337 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_1851698337 crossref_primary_10_1016_j_bbi_2016_12_014 pubmed_primary_28003153 elsevier_sciencedirect_doi_10_1016_j_bbi_2016_12_014 elsevier_clinicalkeyesjournals_1_s2_0_S0889159116305608 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-03-01 |
| PublicationDateYYYYMMDD | 2017-03-01 |
| PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Brain, behavior, and immunity |
| PublicationTitleAlternate | Brain Behav Immun |
| PublicationYear | 2017 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Perregaux, Mcniff, Laliberte, Hawryluk, Peurano, Stam, Eggler, Griffiths, Dombroski, Gabel (b0105) 2001; 299 Jankowsky, Slunt, Ratovitski, Jenkins, Copeland, Borchelt (b0060) 2001; 17 Ghosh, Wu, Shaftel, Kyrkanides, LaFerla, Olschowka, O'Banion (b0030) 2013; 33 Mortimer, Moreau, MacDonald, Chadee (b0095) 2016; 17 Haneklaus, O'Neill (b0045) 2015; 265 Murphy, Grehan, Lynch (b0100) 2014; 16 Kitazawa, Cheng, Tsukamoto, Koike, Wes, Vasilevko, Cribbs, LaFerla (b0075) 2011; 187 Griffin, Stanley, Ling, White, MacLeod, Perrot, White, Araoz (b0035) 1989; 86 Saresella, La Rosa, Piancone, Zoppis, Marventano, Calabrese, Rainone, Nemni, Mancuso, Clerici (b0110) 2016; 11 Halle, Hornung, Petzold, Stewart, Monks, Reinheckel, Fitzgerald, Latz, Moore, Golenbock (b0040) 2008; 9 Cherry, Olschowka, O'Banion (b0010) 2015; 12 Heneka, Kummer, Stutz, Delekate, Schwartz, Vieira-Saecker, Griep, Axt, Remus, Tzeng, Gelpi, Halle, Korte, Latz, Golenbock (b0050) 2013; 493 Minogue, Jones, Kelly, McDonald, Connor, Lynch (b0090) 2014; 35 Coll, Robertson, Chae, Higgins, Munoz-Planillo, Inserra, Vetter, Dungan, Monks, Stutz, Croker, Butler, Haneklaus, Sutton, Nunez, Latz, Kastner, Mills, Masters, Schroder, Cooper, O'Neill (b0015) 2015; 21 Shaftel, Kyrkanides, Olschowka, Miller, Johnson, O'Banion (b0115) 2007; 117 Costello, Keenan, McManus, Falvey, Lynch (b0025) 2016; 43 Costello, Carney, Lynch (b0020) 2015; 46 Heneka, Andreasson, Bachstetter, Colonna, Ginhoux, Holmes, Lamb, Landreth, Lee, Low, Lynch, Monsonego, O'Banion, Pekny, Puschmann, Russek-Blum, Sandusky, Selenica, Takata, Teeling, Town, Van Eldik, Schulz (b0055) 2016 Man, Kanneganti (b0080) 2015; 265 Minogue, Barrett, Lynch (b0085) 2012; 9 Browne, McQuillan, McManus, O'Reilly, Mills, Lynch (b0005) 2013; 190 Tan, Yu, Jiang, Zhu, Wang, Zhang, Wang, Jiang, Tan (b0125) 2013; 265 Jones, Minogue, Fitzpatrick, Lynch (b0065) 2015; 36 Karch, Goate (b0070) 2015; 77 Sutton, Lalor, Sweeney, Brereton, Lavelle, Mills (b0120) 2009; 31 Ghosh (10.1016/j.bbi.2016.12.014_b0030) 2013; 33 Coll (10.1016/j.bbi.2016.12.014_b0015) 2015; 21 Minogue (10.1016/j.bbi.2016.12.014_b0090) 2014; 35 Mortimer (10.1016/j.bbi.2016.12.014_b0095) 2016; 17 Costello (10.1016/j.bbi.2016.12.014_b0020) 2015; 46 Minogue (10.1016/j.bbi.2016.12.014_b0085) 2012; 9 Sutton (10.1016/j.bbi.2016.12.014_b0120) 2009; 31 Browne (10.1016/j.bbi.2016.12.014_b0005) 2013; 190 Cherry (10.1016/j.bbi.2016.12.014_b0010) 2015; 12 Heneka (10.1016/j.bbi.2016.12.014_b0050) 2013; 493 Kitazawa (10.1016/j.bbi.2016.12.014_b0075) 2011; 187 Perregaux (10.1016/j.bbi.2016.12.014_b0105) 2001; 299 Saresella (10.1016/j.bbi.2016.12.014_b0110) 2016; 11 Costello (10.1016/j.bbi.2016.12.014_b0025) 2016; 43 Heneka (10.1016/j.bbi.2016.12.014_b0055) 2016 Griffin (10.1016/j.bbi.2016.12.014_b0035) 1989; 86 Tan (10.1016/j.bbi.2016.12.014_b0125) 2013; 265 Jankowsky (10.1016/j.bbi.2016.12.014_b0060) 2001; 17 Haneklaus (10.1016/j.bbi.2016.12.014_b0045) 2015; 265 Karch (10.1016/j.bbi.2016.12.014_b0070) 2015; 77 Jones (10.1016/j.bbi.2016.12.014_b0065) 2015; 36 Shaftel (10.1016/j.bbi.2016.12.014_b0115) 2007; 117 Halle (10.1016/j.bbi.2016.12.014_b0040) 2008; 9 Man (10.1016/j.bbi.2016.12.014_b0080) 2015; 265 Murphy (10.1016/j.bbi.2016.12.014_b0100) 2014; 16 |
| References_xml | – volume: 9 start-page: 126 year: 2012 ident: b0085 article-title: LPS-induced release of IL-6 from glia modulates production of IL-1 beta in a JAK2-dependent manner publication-title: J. Neuroinflammation contributor: fullname: Lynch – volume: 187 start-page: 6539 year: 2011 end-page: 6549 ident: b0075 article-title: Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model publication-title: J. Immunol. contributor: fullname: LaFerla – volume: 11 start-page: 23 year: 2016 ident: b0110 article-title: The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease publication-title: Mol. Neurodegener. contributor: fullname: Clerici – volume: 265 start-page: 91 year: 2013 end-page: 95 ident: b0125 article-title: NLRP3 polymorphisms are associated with late-onset Alzheimer's disease in Han Chinese publication-title: J. Neuroimmunol. contributor: fullname: Tan – volume: 86 start-page: 7611 year: 1989 end-page: 7615 ident: b0035 article-title: Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease publication-title: Proc. Natl. Acad. Sci U. S. A. contributor: fullname: Araoz – volume: 33 start-page: 5053 year: 2013 end-page: 5064 ident: b0030 article-title: Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model publication-title: J. Neurosci. contributor: fullname: O'Banion – volume: 9 start-page: 857 year: 2008 end-page: 865 ident: b0040 article-title: The NALP3 inflammasome is involved in the innate immune response to amyloid-beta publication-title: Nat. Immunol. contributor: fullname: Golenbock – volume: 265 start-page: 6 year: 2015 end-page: 21 ident: b0080 article-title: Regulation of inflammasome activation publication-title: Immunol. Rev. contributor: fullname: Kanneganti – volume: 190 start-page: 2241 year: 2013 end-page: 2251 ident: b0005 article-title: IFN-gamma Production by amyloid beta-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease publication-title: J. Immunol. contributor: fullname: Lynch – volume: 17 start-page: 1176 year: 2016 ident: b0095 article-title: NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations publication-title: Nat. Immunol. contributor: fullname: Chadee – volume: 265 start-page: 53 year: 2015 end-page: 62 ident: b0045 article-title: NLRP3 at the interface of metabolism and inflammation publication-title: Immunol. Rev. contributor: fullname: O'Neill – volume: 21 start-page: 248 year: 2015 end-page: 255 ident: b0015 article-title: A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases publication-title: Nat. Med. contributor: fullname: O'Neill – volume: 43 start-page: 140 year: 2016 end-page: 148 ident: b0025 article-title: The age-related neuroinflammatory environment promotes macrophage activation, which negatively impacts synaptic function publication-title: Neurobiol. Aging contributor: fullname: Lynch – volume: 16 start-page: 205 year: 2014 end-page: 215 ident: b0100 article-title: Glial uptake of amyloid beta induces NLRP3 inflammasome formation via cathepsin-dependent degradation of NLRP10 publication-title: NeuroMol. Med. contributor: fullname: Lynch – volume: 35 start-page: 1442 year: 2014 end-page: 1452 ident: b0090 article-title: Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice publication-title: Neurobiol. Aging contributor: fullname: Lynch – volume: 31 start-page: 331 year: 2009 end-page: 341 ident: b0120 article-title: Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity publication-title: Immunity contributor: fullname: Mills – volume: 299 start-page: 187 year: 2001 end-page: 197 ident: b0105 article-title: Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors publication-title: J. Pharmacol. Exp. Ther. contributor: fullname: Gabel – volume: 12 start-page: 203 year: 2015 ident: b0010 article-title: Arginase 1+ microglia reduce Abeta plaque deposition during IL-1beta-dependent neuroinflammation publication-title: J Neuroinflammation contributor: fullname: O'Banion – year: 2016 ident: b0055 article-title: Targeting innate immunity for neurodegenerative disorders of the central nervous system publication-title: J. Neurochem. contributor: fullname: Schulz – volume: 117 start-page: 1595 year: 2007 end-page: 1604 ident: b0115 article-title: Sustained hippocampal IL-1beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology publication-title: J. Clin. Invest. contributor: fullname: O'Banion – volume: 17 start-page: 157 year: 2001 end-page: 165 ident: b0060 article-title: Co-expression of multiple transgenes in mouse CNS: a comparison of strategies publication-title: Biomol. Eng. contributor: fullname: Borchelt – volume: 493 start-page: 674 year: 2013 end-page: 678 ident: b0050 article-title: NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice publication-title: Nature contributor: fullname: Golenbock – volume: 46 start-page: 70 year: 2015 end-page: 79 ident: b0020 article-title: Alpha-TLR2 antibody attenuates the Abeta-mediated inflammatory response in microglia through enhanced expression of SIGIRR publication-title: Brain Behav. Immun. contributor: fullname: Lynch – volume: 36 start-page: 2716 year: 2015 end-page: 2724 ident: b0065 article-title: Inhibition of JAK2 attenuates the increase in inflammatory markers in microglia from APP/PS1 mice publication-title: Neurobiol. Aging contributor: fullname: Lynch – volume: 77 start-page: 43 year: 2015 end-page: 51 ident: b0070 article-title: Alzheimer's disease risk genes and mechanisms of disease pathogenesis publication-title: Biol. Psychiatry contributor: fullname: Goate – volume: 16 start-page: 205 year: 2014 ident: 10.1016/j.bbi.2016.12.014_b0100 article-title: Glial uptake of amyloid beta induces NLRP3 inflammasome formation via cathepsin-dependent degradation of NLRP10 publication-title: NeuroMol. Med. doi: 10.1007/s12017-013-8274-6 contributor: fullname: Murphy – volume: 117 start-page: 1595 year: 2007 ident: 10.1016/j.bbi.2016.12.014_b0115 article-title: Sustained hippocampal IL-1beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology publication-title: J. Clin. Invest. doi: 10.1172/JCI31450 contributor: fullname: Shaftel – volume: 265 start-page: 91 year: 2013 ident: 10.1016/j.bbi.2016.12.014_b0125 article-title: NLRP3 polymorphisms are associated with late-onset Alzheimer's disease in Han Chinese publication-title: J. Neuroimmunol. doi: 10.1016/j.jneuroim.2013.10.002 contributor: fullname: Tan – volume: 21 start-page: 248 year: 2015 ident: 10.1016/j.bbi.2016.12.014_b0015 article-title: A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases publication-title: Nat. Med. doi: 10.1038/nm.3806 contributor: fullname: Coll – volume: 265 start-page: 53 year: 2015 ident: 10.1016/j.bbi.2016.12.014_b0045 article-title: NLRP3 at the interface of metabolism and inflammation publication-title: Immunol. Rev. doi: 10.1111/imr.12285 contributor: fullname: Haneklaus – volume: 35 start-page: 1442 year: 2014 ident: 10.1016/j.bbi.2016.12.014_b0090 article-title: Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice publication-title: Neurobiol. Aging doi: 10.1016/j.neurobiolaging.2013.12.026 contributor: fullname: Minogue – volume: 31 start-page: 331 year: 2009 ident: 10.1016/j.bbi.2016.12.014_b0120 article-title: Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity publication-title: Immunity doi: 10.1016/j.immuni.2009.08.001 contributor: fullname: Sutton – volume: 9 start-page: 857 year: 2008 ident: 10.1016/j.bbi.2016.12.014_b0040 article-title: The NALP3 inflammasome is involved in the innate immune response to amyloid-beta publication-title: Nat. Immunol. doi: 10.1038/ni.1636 contributor: fullname: Halle – volume: 43 start-page: 140 year: 2016 ident: 10.1016/j.bbi.2016.12.014_b0025 article-title: The age-related neuroinflammatory environment promotes macrophage activation, which negatively impacts synaptic function publication-title: Neurobiol. Aging doi: 10.1016/j.neurobiolaging.2016.04.001 contributor: fullname: Costello – volume: 17 start-page: 1176 year: 2016 ident: 10.1016/j.bbi.2016.12.014_b0095 article-title: NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations publication-title: Nat. Immunol. doi: 10.1038/ni.3538 contributor: fullname: Mortimer – volume: 187 start-page: 6539 year: 2011 ident: 10.1016/j.bbi.2016.12.014_b0075 article-title: Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model publication-title: J. Immunol. doi: 10.4049/jimmunol.1100620 contributor: fullname: Kitazawa – volume: 190 start-page: 2241 year: 2013 ident: 10.1016/j.bbi.2016.12.014_b0005 article-title: IFN-gamma Production by amyloid beta-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease publication-title: J. Immunol. doi: 10.4049/jimmunol.1200947 contributor: fullname: Browne – volume: 9 start-page: 126 year: 2012 ident: 10.1016/j.bbi.2016.12.014_b0085 article-title: LPS-induced release of IL-6 from glia modulates production of IL-1 beta in a JAK2-dependent manner publication-title: J. Neuroinflammation doi: 10.1186/1742-2094-9-126 contributor: fullname: Minogue – volume: 17 start-page: 157 year: 2001 ident: 10.1016/j.bbi.2016.12.014_b0060 article-title: Co-expression of multiple transgenes in mouse CNS: a comparison of strategies publication-title: Biomol. Eng. doi: 10.1016/S1389-0344(01)00067-3 contributor: fullname: Jankowsky – volume: 12 start-page: 203 year: 2015 ident: 10.1016/j.bbi.2016.12.014_b0010 article-title: Arginase 1+ microglia reduce Abeta plaque deposition during IL-1beta-dependent neuroinflammation publication-title: J Neuroinflammation doi: 10.1186/s12974-015-0411-8 contributor: fullname: Cherry – volume: 11 start-page: 23 year: 2016 ident: 10.1016/j.bbi.2016.12.014_b0110 article-title: The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease publication-title: Mol. Neurodegener. doi: 10.1186/s13024-016-0088-1 contributor: fullname: Saresella – volume: 493 start-page: 674 year: 2013 ident: 10.1016/j.bbi.2016.12.014_b0050 article-title: NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice publication-title: Nature doi: 10.1038/nature11729 contributor: fullname: Heneka – volume: 46 start-page: 70 year: 2015 ident: 10.1016/j.bbi.2016.12.014_b0020 article-title: Alpha-TLR2 antibody attenuates the Abeta-mediated inflammatory response in microglia through enhanced expression of SIGIRR publication-title: Brain Behav. Immun. doi: 10.1016/j.bbi.2015.01.005 contributor: fullname: Costello – year: 2016 ident: 10.1016/j.bbi.2016.12.014_b0055 article-title: Targeting innate immunity for neurodegenerative disorders of the central nervous system publication-title: J. Neurochem. contributor: fullname: Heneka – volume: 33 start-page: 5053 year: 2013 ident: 10.1016/j.bbi.2016.12.014_b0030 article-title: Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.4361-12.2013 contributor: fullname: Ghosh – volume: 86 start-page: 7611 year: 1989 ident: 10.1016/j.bbi.2016.12.014_b0035 article-title: Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease publication-title: Proc. Natl. Acad. Sci U. S. A. doi: 10.1073/pnas.86.19.7611 contributor: fullname: Griffin – volume: 265 start-page: 6 year: 2015 ident: 10.1016/j.bbi.2016.12.014_b0080 article-title: Regulation of inflammasome activation publication-title: Immunol. Rev. doi: 10.1111/imr.12296 contributor: fullname: Man – volume: 36 start-page: 2716 year: 2015 ident: 10.1016/j.bbi.2016.12.014_b0065 article-title: Inhibition of JAK2 attenuates the increase in inflammatory markers in microglia from APP/PS1 mice publication-title: Neurobiol. Aging doi: 10.1016/j.neurobiolaging.2015.04.018 contributor: fullname: Jones – volume: 77 start-page: 43 year: 2015 ident: 10.1016/j.bbi.2016.12.014_b0070 article-title: Alzheimer's disease risk genes and mechanisms of disease pathogenesis publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2014.05.006 contributor: fullname: Karch – volume: 299 start-page: 187 year: 2001 ident: 10.1016/j.bbi.2016.12.014_b0105 article-title: Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors publication-title: J. Pharmacol. Exp. Ther. contributor: fullname: Perregaux |
| SSID | ssj0005318 |
| Score | 2.6741643 |
| Snippet | Highlights • The small molecule inhibitor of the inflammasome, MC950, attenuates Aβ+LPS-induced inflammasome activation in microglia. • It increases... •The small molecule inhibitor of the inflammasome, MC950, attenuates Aβ+LPS-induced inflammasome activation in microglia.•It increases phagocytosis of Aβ by... Activation of the inflammasome is implicated in the pathogenesis of an increasing number of inflammatory diseases, including Alzheimer's disease (AD). Research... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 306 |
| SubjectTerms | Allergy and Immunology Alzheimer Disease - genetics Alzheimer Disease - metabolism Alzheimer’s disease Amyloid beta-Peptides - metabolism Amyloid beta-Protein Precursor - genetics Amyloid beta-Protein Precursor - metabolism Animals APP/PS1 mice Caspase 1 Cognition - drug effects Disease Models, Animal Heterocyclic Compounds, 4 or More Rings - pharmacology Inflammasome Inflammasomes - drug effects Inflammasomes - metabolism Interleukin-1β Mice Microglia Microglia - drug effects Microglia - metabolism Neuroinflammation NLR Family, Pyrin Domain-Containing 3 Protein - metabolism Presenilin-1 - genetics Presenilin-1 - metabolism Psychiatry Sulfones - pharmacology |
| Title | Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0889159116305608 https://dx.doi.org/10.1016/j.bbi.2016.12.014 https://www.ncbi.nlm.nih.gov/pubmed/28003153 https://search.proquest.com/docview/1851698337 |
| Volume | 61 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKKyEuCFo-tsBqkBAHpLDr2Imd4yqi2kJ3FbVU6s1yYlsN0mZXZHvohRO_iB_Cb2LsJIsQKgduUZTElud53njmOSbkDRPS6SqNo6mpyohTk0U6zUwkNJKTMxV3QUSzWKbzS_7xKrnaI_mwF8bLKnvf3_n04K37O5N-NCebup5ceIEOkjHFiAJZ3G_4PUA68rXag9npp_nyt9KjS_MFQY9_YShuBplXWdZe4JWGpCDld9HTXeFnoKGTR-RhHz_CrOviY7Jnm0NyNGtw7by6hbcQFJ0hVX5I7i_6wvkR-X7aXNdl7TXOgCEfLM_OCwaILgTESrfrlQWfkYVFnmfJFDZBpGdbaNZNtLnutgnVFVT-kAmPE1g70Ctc7Ncm-vkDdGNgJ0QCz5Xe3vh9mBXFpLig4E-9f0IuTz58zudRfwBDVPGp3EYi5QZ9YSa1wGk7tcbIWIup5JnBS1FmjCXMVYJRrbVwGa0yK4VLsrhyNHGWPSX72E_7nIDT2mKoKXG9qbljiTRO-vSrTXUprOUj8m4Yd7Xp_rOhBgHaF4VGUt5IisYKjTQiYrCMGjaQosuzbT__WkVVi0-qvzAyInz35h8wU8gg_2rw9WB_hdPP11R0Y9c32JD0hUbJmBiRZx0wdv2PpXeZCTv-v0ZfkAexjyGC4O0l2d9-vbGvMALalmNy7_03Okac5-dnxbjH-y-S2wXQ |
| link.rule.ids | 314,780,784,4502,24116,27924,27925,45585,45679 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELWqVgIuqLRAt3wNEuKAFDaJndg5rlZUW9hdrWgr9WY5_lCDtNlVsz1w4cQv6g_pb2LsJCsQKgduUZTElud55nnmOSbkHeXCKZ2nUWx0GbHEFJHKCxNxhcHJGc1cENHM5vnkgn2-zC53yLjfC-NllZ3vb3168NbdnWE3msN1VQ3PvEAHg3GCjAKjuN_wu8cyZL8I6o8_ftN5tEm-IOfxj_elzSDyKsvKy7vykBJM2H3B6T7yGYLQyT553LFHGLUdfEJ2bH1ADkc1rpyX3-E9BD1nSJQfkAezrmx-SH6e1ldVWXmFMyDhg_n064ICYgvhsFTNamnB52NhNh4XWQzrINGzDdSrOlpftZuEKg3aHzHhUQIrB2qJS_3KRHe3oGoDWxkS-EjprY3fh9FiMVycJeDPvH9KLk4-nY8nUXf8QqRZLDYRz5lBT1gIxXHSxtYYkSoeC1YYvORlQWlGneY0UUpxVyS6sIK7rEi1SzJn6TOyi_20RwScUhaJpsDVpmKOZsI44ZOvNlclt5YNyId-3OW6_cuG7OVn3yQaSXojySSVaKQB4b1lZL99FB2ebbrZ18hENvik_AshA8K2b_4BMonx418Nvu3tL3Hy-YqKqu3qBhsSvswoKOUD8rwFxrb_qfAOM6PH_9foG_Jwcj6byunp_MsL8ij1bCJI316S3c31jX2FXGhTvg5Y_wXHugUU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibiting+the+NLRP3+inflammasome+with+MCC950+promotes+non-phlogistic+clearance+of+amyloid-%CE%B2+and+cognitive+function+in+APP%2FPS1+mice&rft.jtitle=Brain%2C+behavior%2C+and+immunity&rft.au=Dempsey%2C+C.&rft.au=Rubio+Araiz%2C+A.&rft.au=Bryson%2C+K.J.&rft.au=Finucane%2C+O.&rft.date=2017-03-01&rft.issn=0889-1591&rft.volume=61&rft.spage=306&rft.epage=316&rft_id=info:doi/10.1016%2Fj.bbi.2016.12.014&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_bbi_2016_12_014 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0889-1591&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0889-1591&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0889-1591&client=summon |